Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
This is an expanded access/compassionate use protocol that allows access to Mylotarg for relapsed/refractory AML CD33 positive patients in the USA.
Description
The purpose of this study is to allow compassionate access to Mylotarg for treatment of approximately 250 patients with AML who are thought to have the potential to derive clinical benefit and who have exhausted other appropriate and reasonable treatment options including investigational studies.
Details
| Condition | acute myelogenous leukemia |
|---|---|
| Age | 1years - 100years |
| Clinical Study Identifier | TX6399 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.